Top

Published in:

Open Access 01-04-2011

Vitamin D Supplementation in the Pediatric Rheumatology Clinic

Authors: Emily von Scheven, Jon M. Burnham

Published in: Current Rheumatology Reports | Issue 2/2011

Abstract

Vitamin D is capturing the attention of healthy and chronically ill populations for its potential skeletal and nonskeletal benefits. New information suggesting a role in immune modulation has led to a surge of interest among rheumatologists. Although the epidemiologic data are limited, it appears that many children with rheumatic conditions are at risk of vitamin D deficiency. However, understanding this phenomenon requires an appreciation for how vitamin D status is assessed, and options for supplementation. Although a “more-is-better” attitude is tempting when considering the medicinal effects of a nutritional supplement, we suggest a cautious approach and suggest that further studies are needed to clarify the potential benefits and risks among children with rheumatic conditions.

Holick, M.F., Vitamin D deficiency. N Engl J Med, 2007. 357(3): p. 266–81.PubMedCrossRef

Chen, T.C., et al., Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys, 2007. 460(2): p. 213–7.PubMedCrossRef

Heaney, R.P., Vitamin D endocrine physiology. J Bone Miner Res, 2007. 22 Suppl 2: p. V25–7.

Adams, J.S. and M. Hewison, Update in vitamin D. J Clin Endocrinol Metab. 95(2): p. 471–8.

Wharton, B. and N. Bishop, Rickets. Lancet, 2003. 362(9393): p. 1389–400.PubMedCrossRef

Bischoff-Ferrari, H., Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary? Best Pract Res Clin Rheumatol, 2009. 23(6): p. 789–95.PubMedCrossRef

El-Hajj Fuleihan, G., et al., Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab, 2006. 91(2): p. 405–12.PubMedCrossRef

Viljakainen, H.T., et al., A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention. J Bone Miner Res, 2006. 21(6): p. 836–44.PubMedCrossRef

Ward, K.A., et al., A randomized, controlled trial of vitamin D supplementation upon musculoskeletal health in postmenarchal females. J Clin Endocrinol Metab. 95(10): p. 4643–51.

10.

Norman, A.W., et al., Vitamin D deficiency inhibits pancreatic secretion of insulin. Science, 1980. 209(4458): p. 823–5.PubMedCrossRef

11.

Takiishi, T., et al., Vitamin D and diabetes. Endocrinol Metab Clin North Am. 39(2): p. 419–46, table of contents.

12.

Chiu, K.C., et al., Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr, 2004. 79(5): p. 820–5.PubMed

13.

Reis, J.P., et al., Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics, 2009. 124(3): p. e371–9.PubMedCrossRef

14.

Ashraf, A., et al., Threshold for effects of vitamin D deficiency on glucose metabolism in obese female African-American adolescents. J Clin Endocrinol Metab, 2009. 94(9): p. 3200–6.PubMedCrossRef

15.

Pittas, A.G., et al., Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 152(5): p. 307–14.

16.

Giovannucci, E., et al., 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med, 2008. 168(11): p. 1174–80.PubMedCrossRef

17.

Wang, T.J., et al., Vitamin D deficiency and risk of cardiovascular disease. Circulation, 2008. 117(4): p. 503–11.PubMedCrossRef

18.

Dobnig, H., et al., Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med, 2008. 168(12): p. 1340–9.PubMedCrossRef

19.

Kilkkinen, A., et al., Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol, 2009. 170(8): p. 1032–9.PubMedCrossRef

20.

Liu, P.T., et al., Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006. 311(5768): p. 1770–3.PubMedCrossRef

21.

Gauzzi, M.C., et al., Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol, 2005. 174(1): p. 270–6.PubMed

22.

Pelajo, C.F., J.M. Lopez-Benitez, and L.C. Miller, Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev. 9(7): p. 507–10.

23.

•• Adams, J.S. and M. Hewison, Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab, 2008. 4(2): p. 80–90. This is an excellent review of the potential mechanisms underlying a role for vitamin D in autoimmune diseases.PubMedCrossRef

24.

Penna, G., et al., 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol, 2007. 178(1): p. 145–53.PubMed

25.

Adorini, L., N. Giarratana, and G. Penna, Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol, 2004. 16(2): p. 127–34.PubMedCrossRef

26.

Daniel, C., et al., Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther, 2008. 324(1): p. 23–33.PubMedCrossRef

27.

Giarratana, N., et al., A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol, 2004. 173(4): p. 2280–7.PubMed

28.

Chen, S., et al., Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol, 2007. 179(3): p. 1634–47.PubMed

29.

Garland, C.F. and F.C. Garland, Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol, 1980. 9(3): p. 227–31.PubMedCrossRef

30.

Toner, C.D., C.D. Davis, and J.A. Milner, The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc. 110(10): p. 1492–500.

31.

Bultink, I.E., et al., Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum, 2005. 52(7): p. 2044–50.PubMedCrossRef

32.

• Wright, T.B., et al., Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr, 2009. 155(2): p. 260–5. This was an observational study characterizing the vitamin D status of children with SLE and the interaction with obesity.PubMedCrossRef

33.

Ben-Zvi, I., et al., The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One. 5(2): p. e9193.

34.

Mowry, E.M., et al., Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 67(5): p. 618–24.

35.

•• Wagner, C.L. and F.R. Greer, Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics, 2008. 122(5): p. 1142–52. This article lists the American Academy of Pediatrics’ recommendations for vitamin D intake in children.PubMedCrossRef

36.

Bischoff-Ferrari, H.A., et al., Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr, 2006. 84(1): p. 18–28.PubMed

37.

Holick, M.F., High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc, 2006. 81(3): p. 353–73.PubMedCrossRef

38.

Malabanan, A., I.E. Veronikis, and M.F. Holick, Redefining vitamin D insufficiency. Lancet, 1998. 351(9105): p. 805–6.PubMedCrossRef

39.

Holick, M.F. and T.C. Chen, Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr, 2008. 87(4): p. 1080S–6S.PubMed

40.

Lenders, C.M., et al., Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am J Clin Nutr, 2009. 90(3): p. 459–67.PubMedCrossRef

41.

Reed, A., et al., Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. J Pediatr, 1990. 116(4): p. 574–80.PubMedCrossRef

42.

Pepmueller, P.H., et al., Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum, 1996. 39(5): p. 746–57.PubMedCrossRef

43.

•• Kamen, D.L., Vitamin D in lupus—new kid on the block? Bull NYU Hosp Jt Dis. 2010, 68(3): p. 218–22. This is an insightful article examining the newly emerging role for vitamin D.PubMed

44.

Toloza, S.M., et al., Vitamin D insufficiency in a large female SLE cohort. Lupus. 19(1): p. 13–9.

45.

Bischoff-Ferrari, H.A., Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol, 2008. 624: p. 55–71.PubMedCrossRef

46.

•• Institute of Medicine of the National Academies: Dietary reference intakes for vitamin D and calcium. Available at http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx. This is a new statement by the Institute of Medicine synthesizing recent literature and providing guidelines for dietary intake and target levels of vitamin D.

47.

Avenell, A., et al., Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev, 2009(2): p. CD000227.

48.

Armas, L.A., B.W. Hollis, and R.P. Heaney, Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab, 2004. 89(11): p. 5387–91.PubMedCrossRef

49.

Trang, H.M., et al., Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr, 1998. 68(4): p. 854–8.PubMed

50.

Heaney, R.P., et al., Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr, 2003. 77(1): p. 204–10.PubMed

51.

Kilpinen-Loisa, P., et al., High-dose vitamin D supplementation in children with cerebral palsy or neuromuscular disorder. Neuropediatrics, 2007. 38(4): p. 167–72.PubMedCrossRef

Title: Vitamin D Supplementation in the Pediatric Rheumatology Clinic
Authors: Emily von Scheven
Jon M. Burnham
Publication date: 01-04-2011
Publisher: Current Science Inc.
Published in: Current Rheumatology Reports / Issue 2/2011
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-010-0161-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Quality of Care in Patients with Gout: Why is Management Suboptimal and What Can Be Done About It?

Effects of Dairy Intake on Hyperuricemia and Gout

The Role of Uric Acid as an Endogenous Danger Signal in Immunity and Inflammation

The Immune System, the Skin, and Childhood Rheumatic Disease

Large Epidemiologic Studies of Gout: Challenges in Diagnosis and Diagnostic Criteria

Current Status of Understanding the Pathogenesis and Management of Patients With NOMID/CINCA

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials